Acorda Therapeutics, Inc. ACOR today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 11/102,559 entitled “Method of Using Sustained Release Aminopyridine Compositions.” The claims of the patent application relate to methods to improve walking, walking speed, lower extremity muscle tone and lower extremity muscle strength in patients with multiple sclerosis by administering 10 mg of sustained release 4-aminopyridine (dalfampridine) twice daily. This patent application is separate from the AMPYRA® method of use patent application which was allowed by the USPTO in April 2011.
“The allowance of this patent application further strengthens our patent protection for AMPRYA and enhances our ability to continue exploring potential new uses and indications, both in MS and other diseases,” said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. “The discoveries we made during our development of AMPYRA, several of which are reflected in this patent, were critical to receiving FDA approval and making this therapy available to people with MS who have walking impairment. We are pleased that the UPTO has recognized these findings as innovative and valuable contributions to medicine.”
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in